Business
The First and Only Tazarotene Lotion indicated for Acne Vulgaris in Patients 10 Years of Age and Older, ARAZLO(TM) now Available for Patients by Prescription across Canada
The First and Only Tazarotene Lotion indicated for Acne Vulgaris in Patients 10 Years of ...
About this update from Bausch Health Companies Inc.
[{"type":"text","content":"\n \n \n \n The First and Only Tazarotene Lotion indicated for Acne Vulgaris in Patients 10 Years of Age and Older, ARAZLO™ now Available for Patients by Prescription across Canada\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Shown to provide strong efficacy with good tolerability profile\n \n \n \n \n LAVAL, QC\n \n ,\n \n Oct. 28, 2021\n \n /CNW Telbec/ - Bausch Health,\n \n Canada\n \n , which is part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) (\"Bausch Health\" or the \"Company\"), and its dermatology division, one of the largest prescription dermatology health care businesses in Canada, today announced that its new topical prescription treatment for acne vulgaris (common acne), ARAZLO\n \n TM\n \n (tazarotene) lotion, 0.045% w/w, for patients 10 years of age and older\n \n 1\n \n is now available across\n \n Canada\n \n .\n \n \n \n \n \n \n \n \n \n ARAZLO is the first tazarotene 0.045% w/w lotion treatment formulated with PRISMATREX\n \n TM\n \n technology approved by Health Canada that delivers the benefits of tazarotene in a formulation with known hydrating and moisturizers to effectively treat acne with demonstrated efficacy and tolerability.\n \n 1\n \n \n \n \"We are very pleased that ARAZLO is now available for prescription by doctors across\n \n Canada\n \n as an important new option for them to help treat the approximately 5.6 million Canadians who are impacted by acne,\"\n \n 2\n \n said Ginette Gagné, Interim President and General Manager, Bausch Health,\n \n Canada\n \n . \"We are proud to be expanding our already large dermatology portfolio to better help meet Canadians' needs.\"\n \n \n \"The availability of ARAZLO provides an important new addition to how we can help our patients with acne by providing access to treatment by the powerful retinoid tazarotene in a lotion form that will help limit the dryness and irritation that has historically been a barrier to its long-term use by patients,\"\n \n 3\n \n said Dr.\n \n Benjamin Barankin\n \n , MD, FRCPC, FAAD ȁ...